找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Therapy; Monoclonal Antibodie Hans G. Beger (Professor of Surgery),Markus Büchle Conference proceedings 1989 Springer-Verlag Berlin

[復(fù)制鏈接]
樓主: Denial
21#
發(fā)表于 2025-3-25 04:26:23 | 只看該作者
J. I. Sprent,F. R. Minchin,R. Parsonsthe treatment of advanced melanoma in 24 patients [1]. In this report, we present results on the first 30 patients treated with this regimen. Our rationale for giving low-dose CY was to inhibit suppressor T cells, the number and activity of which might be increased by IL-2, thereby possibly preventi
22#
發(fā)表于 2025-3-25 11:34:30 | 只看該作者
23#
發(fā)表于 2025-3-25 15:27:33 | 只看該作者
24#
發(fā)表于 2025-3-25 16:11:20 | 只看該作者
New Horizons in Occultation Researchferentiation and mature myeloid cell function. With the availability of large quantities of these agents in recombinant form [1–4], it was soon demonstrated that they could as well increase the rate of myeloid cell proliferation in vivo and increase blood myeloid cell numbers [5–8]. The most obvious
25#
發(fā)表于 2025-3-25 23:17:00 | 只看該作者
New Horizons in Occultation Research of cancer, particularly since in 1981 highly purified material produced by recombinant DNA technology has become available in addition to natural IFNs [25, 51, 59]. So far, the most impressive clinical results have been achieved in hematologic disorders, especially in hairy cell leukemia [26, 41, 5
26#
發(fā)表于 2025-3-26 02:30:59 | 只看該作者
27#
發(fā)表于 2025-3-26 04:30:20 | 只看該作者
New Horizons in Occultation Researchkes stages, the 5-year-survival rates never exceeded 50% [1, 2]. Surgical progress has been restricted to the development of sphincter-saving procedures for rectal cancer at low levels [3–6]. However, an improvement in the prognosis of colorectal cancer patients should not be expected from surgery a
28#
發(fā)表于 2025-3-26 10:56:35 | 只看該作者
J. I. Sprent,F. R. Minchin,R. Parsonsng an increase in the number of helper and cytolytic T cells and in lymphokine-activated killer (LAK) cells as well. The dose of IL-2 was chosen to be at or near the projected maximum tolerated single dose level, as estimated from Phase I data.
29#
發(fā)表于 2025-3-26 15:06:15 | 只看該作者
30#
發(fā)表于 2025-3-26 17:46:04 | 只看該作者
Conference proceedings 1989nd radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and mon
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 17:05
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
沙洋县| 民丰县| 江陵县| 威信县| 南靖县| 民权县| 巴青县| 出国| 云梦县| 绥德县| 阳泉市| 莆田市| 湘阴县| 南江县| 大竹县| 德江县| 剑阁县| 安陆市| 呼伦贝尔市| 射阳县| 湘乡市| 库伦旗| 钟山县| 昌吉市| 和林格尔县| 葫芦岛市| 南充市| 建水县| 南雄市| 凤山县| 平谷区| 荥阳市| 岳普湖县| 荆州市| 渝中区| 灵石县| 望奎县| 永泰县| 乌拉特后旗| 东莞市| 望谟县|